Have you seen ? Pink 1 , the first ubiquitin kinase
Xinde Zheng,T. Hunter
2014-01-01
Abstract:P ink1, a mitochondrial kinase, and Parkin, a cytosolic E3 ubiquitin ligase, function in mitochondrial maintenance. Pink1 is normally imported into mitochondria, cleaved by PARL protease, and degraded by the proteasome. When mitochondria lose their membrane potential, Pink1 starts to accumulate on the mitochondrial outer surface, where it recruits and activates Parkin to trigger protein ubiquitination, eventually leading to mitochondrial autophagy (reviewed in Narendra et al, 2012). Parkin E3 ubiquitin ligase activity is inhibited by its N-terminal ubiquitin-like (UBL) domain through interaction with C-terminal RING-between-RING (RBR) E3 catalytic domain (Chaugule et al, 2011). Recombinant Pink1 can phosphorylate the UBL domain at Ser65 in vitro, and Parkin Ser65 phosphorylation is readily detected when mitochondria are depolarized (Kondapalli et al, 2012; Shiba-Fukushima et al, 2012). A simplified model is that Pink1 phosphorylation of Ser65 in the UBL domain releases Parkin autoinhibition. However, phospho-mimetic substitution (Ser65Glu) or even UBL domain deletion cannot bypass the requirement of Pink1 for Parkin activation (Sarraf et al, 2013). Are there any other Pink1 substrate(s) or Parkin phosphorylation sites involved in Parkin activation? Three recent reports provide an unexpected answer: Pink1 directly phosphorylates ubiquitin, and this is critical for Parkin activation (Kane et al, 2014; Kazlauskaite et al, 2014; Koyano et al, 2014). This discovery represents the first example of a functional phosphorylation on ubiquitin. To identify the full spectrum of Pink1 substrates, proteomic approaches were used to compare the profile of mitochondria isolated from wild-type or Pink1-deficient cells after treatment by CCCP, a mitochondria-depolarizing drug (Kane et al, 2014; Kazlauskaite et al, 2014). Surprisingly, a phosphopeptide identified in mitochondriaassociated proteins only in wild-type cells derives from ubiquitin, and phosphorylation occurs at the conserved Ser65 residue, which corresponds to Ser65 in the Parkin UBL. Based on structural similarity between ubiquitin and the UBL domain, Koyano et al (2014) hypothesized that Ser65 on ubiquitin may be phosphorylated by Pink1, and indeed ubiquitin in CCCP-treated lysates exhibited a phosphorylation-dependent electrophoresis band-shift, and the same phospho-Ser65 peptide could be identified by mass spectrometry. Quantification showed that phospho-ubiquitin represents 0.05% of total endogenous ubiquitin, although it is not known whether all the pSer65 ubiquitin molecules are associated with mitochondria. The kinase–substrate relationship was further established by in vitro kinase assays, in which recombinant Pink1 could phosphorylate wild-type but not S65A ubiquitin (Kane et al, 2014; Kazlauskaite et al, 2014; Koyano et al, 2014). Does phospho-S65 ubiquitin play any role in Parkin regulation, and is there any interplay between Ser65 ubiquitin and Parkin UBL domain Ser65 phosphorylation? Using in vitro Parkin E3 activity assays, all three groups provide compelling evidence that both phosphorylations are involved in and required for full Parkin activation. Kazlauskaite et al found that substituting wild-type ubiquitin with S65A ubiquitin greatly diminished Parkin E3 activity, but Parkin with a UBL S65A mutation also had much lower activity compared to wild-type Parkin, indicating that both phosphorylations are required. Kane et al found that prephosphorylation of ubiquitin by recombinant Pink1 could significantly enhance Parkin-mediated protein ubiquitination in vitro. Using GFP-Parkin and purified depolarized mitochondria as a source of Pink1, Koyano et al found that phospho-mimetic S65D ubiquitin, but not WT or S65A ubiquitin, could stimulate autoubiquitination of GFP-S65E-Parkin bearing an additional phospho-mimetic substitution in the UBL domain, but observed no enhancement with GFP-WT-Parkin. How does the phospho-Ser65 ubiquitin activate Parkin? Koyano et al showed that phospho-mimetic S65D ubiquitin with a C-terminal diglycine mutation, which abolishes its conjugation to target proteins, could still activate the E3 activity of Parkin, excluding the possibility that phospho-S65 ubiquitin is preferred by Parkin for conjugation. They further showed that phosphomimetic S65D ubiquitin binds to S65E Parkin, but not WT Parkin. The activation mechanism appears to be allosteric and allows functional access of Parkin to its cognate ubiquitin-conjugating E2 enzyme, since phospho-S65 ubiquitin accelerates Parkin discharge of UBCH7~ubiquitin (Kazlauskaite et al, 2014; Koyano et al, 2014). In summary, these studies uncover a surprising missing link in Parkin activation (Fig 1). To understand how phospho-ubiquitin activates Parkin, the next step is to identify the exact binding site for phosphoSer65-ubiquitin on Parkin, which was not